Assessing readiness to implement long-acting injectable HIV antiretroviral therapy: provider and staff perspectives

被引:4
|
作者
Koester K.A. [1 ]
Colasanti J.A. [2 ]
McNulty M.C. [3 ,4 ]
Dance K. [2 ]
Erguera X.A. [5 ]
Tsuzuki M.D. [5 ]
Johnson M.O. [1 ]
Sauceda J.A. [1 ]
Montgomery E. [6 ,7 ]
Schneider J. [3 ,4 ]
Christopoulos K.A. [5 ]
机构
[1] Division of Prevention Science, University of California, San Francisco, 550 16th Street, San Francisco, 94105, CA
[2] Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA
[3] Chicago Center for HIV Elimination, University of Chicago, Chicago
[4] Section of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, IL
[5] Division of HIV, ID and Global Medicine, Department of Medicine, University of California San Francisco, San Francisco, CA
[6] Women’s Global Health Imperative, RTI International, Berkeley, CA
[7] Department of Epidemiology and Biostatistics, School of Medicine, University of California San Francisco, San Francisco, CA
基金
美国国家卫生研究院;
关键词
CFIR; Focus groups; HIV antiretroviral therapy; Long-acting injectable medication; Pre-implementation; Qualitative methods;
D O I
10.1186/s43058-023-00506-3
中图分类号
学科分类号
摘要
Background: Long-acting injectable antiretroviral therapy (LAI-ART) represents the next innovation in HIV therapy. Pre-implementation research is needed to develop effective strategies to ensure equitable access to LAI-ART to individuals living with HIV. Methods: We conducted focus group discussions (FGDs) with providers and staff affiliated with HIV clinics in San Francisco, Chicago, and Atlanta to understand barriers to and facilitators of LAI-ART implementation. Participants also completed a short survey about implementation intentions. FGDs were held via video conference, recorded, transcribed, and thematically analyzed using domains associated with the Consolidated Framework for Implementation Research (CFIR). Results: Between September 2020 and April 2021, we led 10 FDGs with 49 participants, of whom ~60% were prescribing providers. Organizational readiness for implementing change was high, with 85% agreeing to being committed to figuring out how to implement LAI-ART. While responses were influenced by the unique inner and outer resources available in each setting, several common themes, including implementation mechanisms, dominated: (1) optimism and enthusiasm about LAI-ART was contingent on ensuring equitable access to LAI-ART; (2) LAI-ART shifts the primary responsibility of ART adherence from the patient to the clinic; and (3) existing clinic systems require strengthening to meet the needs of patients with adherence challenges. Current systems in all sites could support the use of LAI-ART in a limited number of stable patients. Scale-up and equitable use would be challenging or impossible without additional personnel. Participants outlined programmatic elements necessary to realize equitable access including centralized tracking of patients, capacity for in-depth, hands-on outreach, and mobile delivery of LAI-ART. Sites further specified unknown logistical impacts on implementation related to billing/payer source as well as shipping and drug storage. Conclusions: Among these HIV care sites, clinic readiness to offer LAI-ART to a subset of patients is high. The main challenges to implementation include concerns about unequal access and a recognition that strengthening the clinic system is critical. © 2023, BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [1] Long-acting injectable antiretroviral therapy: will it change the future of HIV treatment?
    Brizzi, Marisa
    Perez, Sarah E.
    Michienzi, Sarah M.
    Badowski, Melissa E.
    [J]. THERAPEUTIC ADVANCES IN INFECTIOUS DISEASE, 2023, 10
  • [2] Long-acting injectable antiretroviral therapy for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (10) : E341 - E342
  • [3] Long-Acting Injectable Antiretroviral Agents for HIV Treatment and Prevention
    Kim, Yeon-Sook
    [J]. INFECTION AND CHEMOTHERAPY, 2021, 53 (04): : 686 - 695
  • [4] Acceptability of Long-Acting Injectable Antiretroviral Treatment for HIV Management: Perspectives of Patients and Physicians in Spain
    Moreno, Cristina
    Izquierdo, Rebeca
    Alejos, Belen
    Hernando, Victoria
    de la Camara, Santiago Perez
    Peraire, Joaquim
    Macias, Juan
    Bernal, Enrique
    Albendin-Iglesias, Helena
    Alcaraz, Begona
    Suarez-Garcia, Ines
    Moreno, Santiago
    Jarrin, Inma
    [J]. AIDS PATIENT CARE AND STDS, 2024, 38 (07) : 305 - 314
  • [5] WOMEN'S PERSPECTIVES OF LONG-ACTING INJECTABLE ANTIRETROVIRAL THERAPY IN US HIV HEALTHCARE SETTINGS FROM THE CUSTOMIZE STUDY
    Salazar, D.
    Thedinger, B.
    Benson, P.
    Garris, C.
    Stassek, L.
    Mansukhani, S. G.
    D'Amico, R.
    Nwafor, T.
    Dalessandro, M.
    Petty, L.
    Czarnogorski, M.
    [J]. VALUE IN HEALTH, 2021, 24 : S120 - S120
  • [6] Long-acting injectable antiretroviral for HIV-1 infection in adults
    Halani, Sheliza
    Tan, Darrell
    Andany, Nisha
    [J]. CANADIAN MEDICAL ASSOCIATION JOURNAL, 2024, 196 (25) : E888 - E889
  • [7] Patient and clinic staff perspectives on the implementation of a long-acting injectable antiretroviral therapy program in an urban safety-net health system
    Agovi, Afiba Manza-A
    Thompson, Caitlin T.
    Craten, Kevin J.
    Fasanmi, Esther
    Pan, Meng
    Ojha, Rohit P.
    Thompson, Erika L.
    [J]. IMPLEMENTATION SCIENCE COMMUNICATIONS, 2024, 5 (01):
  • [8] Perspectives Among Health Care Providers and People with HIV on the Implementation of Long-Acting Injectable Cabotegravir/Rilpivirine for Antiretroviral Therapy in Florida
    Fisk-Hoffman, Rebecca J.
    Ranger, Sashaun S.
    Gracy, Abigail
    Gracy, Hannah
    Manavalan, Preeti
    Widmeyer, Maya
    Leeman, Robert F.
    Cook, Robert L.
    Canidate, Shantrel
    [J]. AIDS PATIENT CARE AND STDS, 2024, 38 (06) : 275 - 285
  • [9] Long-acting antiretroviral therapy
    Soriano, Vicente
    Barreiro, Pablo
    de Mendoza, Carmen
    [J]. NATURE MATERIALS, 2020, 19 (08) : 826 - 827
  • [10] Long-acting antiretroviral therapy
    Vicente Soriano
    Pablo Barreiro
    Carmen de Mendoza
    [J]. Nature Materials, 2020, 19 : 826 - 827